Industry News

Nektar Therapeutics will announce its financial results for the second quarter ended June 30, 2016, on Wednesday, August 3, 2016, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/ 2:00 p.m. Pacific Time. The press release and a live audio-only Webcast of the conference call can be accessed through a..."/>
Nektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’ s disease and diabetes, today..."/>
VTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer’s Association International Conference (AAIC)
Cigna "remains as strong as ever," company officials said Wednesday. Indianapolis-based Anthem planned to close on its purchase of Cigna in a $48 billion deal by the end of 2016, but after the U.S. Department of Justice filed a lawsuit to block the sale, that is unlikely to happen."/>
Anthem: Commitment to Buying Cigna As Strong As Ever [The Hartford Courant]
Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today announced the company plans to participate in Canaccord Genuity’ s Growth Conference in Boston, Massachusetts. Senseonics’ management is scheduled to present Wednesday, August 10, 2016 at 10:00 a.m. EDT. Interested parties can access the live audio..."/>
Senseonics Holdings, Inc. to present at Canaccord Genuity’s Growth Conference
Crescita Therapeutics Inc., a drug development company that owns topical products for treating medical conditions in dermatology and pain, today announced its financial and operational results for the second quarter ended June 30, 2016. The Company commenced operations on a stand-alone basis on March 1, 2016, the effective date of a reorganization of the former Nuvo Research Inc. pursuant to which certain development stage..."/>
Crescita Therapeutics™ Announces 2016 Second Quarter Results
Crescita Therapeutics Inc., a drug development company that owns topical products for treating medical conditions in dermatology and pain, today announced its financial and operational results for the second quarter ended June 30, 2016. The Company commenced operations on a stand-alone basis on March 1, 2016, the effective date of a reorganization of the former Nuvo Research Inc. pursuant to which certain development stage products and..."/>
Crescita Therapeutics™ Announces 2016 Second Quarter Results
Array BioPharma Inc. will report financial results for the fourth quarter and full year of fiscal 2016 and hold a conference call to discuss those results on Thursday, August 4, 2016. Ron Squarer, Chief Executive Officer, will lead the call. About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted..."/>
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2016 On August 4, 2016
CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the second quarter ended June 30, 2016, and provide a mid-year update on August 3, 2016, after the NASDAQ market close.. The company will not be conducting a conference call in conjunction with this earnings release. About CytomX Therapeutics CytomX is an..."/>
CytomX Therapeutics to Announce Second Quarter 2016 Financial Results and Provide Mid-Year Update
Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company, today announced the appointment of Daniel M. Junius to its board of directors, effective immediately. Junius recently retired as President and Chief Executive Officer of ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics, a position he held since January 2009.. “On behalf of the board of directors, I am pleased to welcome Dan to Vitae."/>
Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors
MacroGenics, Inc. today announced that on Wednesday, August 3, 2016, the Company will release its financial results for the quarter ended June 30, 2016. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Wednesday, August 3, 2016 at 4:30 pm."/>
MacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call
Healthways, including: Gallup-Healthways Well-Being Index ®; Innergy Healthier Weight, a collaboration with Johns Hopkins Medicine that provides a high-touch, personalized solution proven to sustain weight loss; its two Emerging Solutions businesses, Dan Buettner’ s Blue Zones Project ® and..."/>
Sharecare Acquires Healthways’ Population Health Business, Secures Leadership Position in Employer and Health Plan Markets
Healthways today announced it completed its strategic assessment that began in October 2015."/>
Healthways Completes Strategic Assessment
VIVUS, Inc. today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Hetero USA, Inc. and Hetero Labs Limited, collectively referred to as Hetero. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Hetero."/>
VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
Varian Medical Systems, today announced it has been selected to install and service its ProBeam ® proton therapy system in the new multi-room Hefei Ion Medical Center being built in Hefei, Anhui Province, China. The company booked the order for the equipment as well as its ARIA ® information management and Eclipse™ treatment planning software in the third quarter of its fiscal year 2016.. HIMC will be the first government-owned proton..."/>
Varian Chosen to Equip First Government Owned Proton Center in China
PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on July 27, 2016. This dividend is payable on November 10, 2016 to all shareholders of record at the close of business on October 14, 2016.. About PerkinElmer PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment."/>
PerkinElmer Board Declares Quarterly Dividend
PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that Frank Witney, Ph.D., has been elected to the Company’ s Board of Directors. “I am delighted to welcome Frank to PerkinElmer’ s Board, as he brings deep market knowledge and over 30 years of leadership experience across the life sciences, diagnostics and analytical instruments industry,” said Robert Friel, Chairman and Chief Executive Officer,..."/>
PerkinElmer Elects Frank Witney to Board of Directors
Molina Healthcare, Inc.:. Net income per diluted share for the quarter of $0.58. Adjusted net income per diluted share for the quarter of $0.67. Net income per diluted share for the quarter up 35% over first quarter 2016. Adjusted net income per diluted share for the quarter up 31% over first quarter 2016. Total revenue for the quarter of $4.4 billion, up 24% over second quarter 2015. Aggregate membership up 26% over second quarter 2015.. Molina Healthcare, Inc...."/>
Molina Healthcare Reports Second Quarter 2016 Results
Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2016.. Total revenues were $39.1 million as compared to $35.2 million in the second quarter of 2015. Solana ® Trichomonas assay received CE Mark. Sofia ® Strep A+ FIA approved in Japan. Sofia ® Influenza A+ B FIA approved in Singapore. Sofia ® hCG FIA..."/>
Quidel Reports Second Quarter 2016 Financial Results
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that, as anticipated, it received written communication from the U.S. Food and Drug Administration outlining information required to resolve the clinical hold for its Investigational New Drug for RG-101, which was announced on June 27, 2016.. In the written communication, the FDA..."/>
Regulus Provides Update on Clinical Hold of RG-101
McKesson Reports Fiscal 2017 First-Quarter Results
Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis ® technology platform, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities to be sold in the offering will be offered..."/>
Argos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Varian Medical Systems today is reporting GAAP net earnings of $1.04 per diluted share and non-GAAP net earnings of $1.22 per diluted share for the third quarter of fiscal year 2016. Varian's revenues totaled $789 million for the third quarter, up 1 percent from the year-ago quarter in dollars and even with the year-ago quarter in constant currency. The company ended the quarter with a $3.3 billion backlog, up 5 percent from the end of the..."/>
Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2016

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials722 Articles
Information Technology705 Articles
Consumer Discretionary624 Articles
Industrials467 Articles
Health Care422 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.